Jérôme Alexandre
YOU?
Author Swipe
View article: Supplementary Table S5 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Supplementary Table S5 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer Open
List of BRCA variants detected by both GIScar tests and MGMC tests
View article: Supplementary Appendix S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Supplementary Appendix S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer Open
PAOLA-1 Investigators
View article: Supplementary Table S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Supplementary Table S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer Open
prospective collection used to train GIScar (n = 250)
View article: Supplementary Figure S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Supplementary Figure S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer Open
PFS in patients according to GIScar (left panel) and MGMC scores (right panel).
View article: Supplementary Table S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Supplementary Table S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer Open
Histologic type of tumors used in this study (n = 719)
View article: Supplementary Figure S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Supplementary Figure S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer Open
Additional information regarding the GIScar training (N = 250 tumors).
View article: Supplementary Figure S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Supplementary Figure S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer Open
Kaplan–Meier estimates of PFS stratified on treatment arm (n = 469).
View article: Fertility preservation in women with sarcoma: A real‐world experience
Fertility preservation in women with sarcoma: A real‐world experience Open
Sarcomas frequently affect adolescent girls and young women, for whom future fertility is a critical concern. The urgency of initiating treatment—due to rapid tumor progression and the need for extensive diagnostic evaluation—often limits …
View article: Pembrolizumab in patients with rare ovarian cancers : analysis from AcSé Pembrolizumab phase II multicentric basket trial
Pembrolizumab in patients with rare ovarian cancers : analysis from AcSé Pembrolizumab phase II multicentric basket trial Open
Rare ovarian cancer is a heterogeneous group of diseases with significant unmet medical needs and low chemotherapy sensitivity. In this context, the AcSé Pembrolizumab (NCT03012620) multicentric, non-randomized, phase II basket trial, asse…
View article: Data from Droplet Digital PCR Assay for Detection and Monitoring of Universally Methylated ctDNA in Patients with Sarcoma
Data from Droplet Digital PCR Assay for Detection and Monitoring of Universally Methylated ctDNA in Patients with Sarcoma Open
Purpose:No universal circulating biomarker exists for soft-tissue sarcoma (STS) and bone sarcoma. We report the translational relevance of a Droplet Digital PCR (ddPCR) assay allowing universal, specific, and dynamic detection of sarcoma-r…
View article: Supplementals 1 from Droplet Digital PCR Assay for Detection and Monitoring of Universally Methylated ctDNA in Patients with Sarcoma
Supplementals 1 from Droplet Digital PCR Assay for Detection and Monitoring of Universally Methylated ctDNA in Patients with Sarcoma Open
Supplementals
View article: Supplemental Data 1 from Droplet Digital PCR Assay for Detection and Monitoring of Universally Methylated ctDNA in Patients with Sarcoma
Supplemental Data 1 from Droplet Digital PCR Assay for Detection and Monitoring of Universally Methylated ctDNA in Patients with Sarcoma Open
Supplemental Data 1
View article: Supplemental Data 2 from Droplet Digital PCR Assay for Detection and Monitoring of Universally Methylated ctDNA in Patients with Sarcoma
Supplemental Data 2 from Droplet Digital PCR Assay for Detection and Monitoring of Universally Methylated ctDNA in Patients with Sarcoma Open
Supplemental Data 2
View article: Clinical outcome of advanced or recurrent endometrial carcinoma treated with chemotherapy: a French observational retrospective cohort: the ENDOVIE study
Clinical outcome of advanced or recurrent endometrial carcinoma treated with chemotherapy: a French observational retrospective cohort: the ENDOVIE study Open
Objective Advanced or recurrent endometrial carcinoma (EC) represents a significant clinical challenge. This study aimed to evaluate patient (age and comorbidities) and disease (histological subtypes and stages) characteristics, treatment …
View article: Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial Open
View article: Improved tumor-type informed compared to tumor-informed mutation tracking for ctDNA detection and microscopic residual disease assessment in epithelial ovarian cancer
Improved tumor-type informed compared to tumor-informed mutation tracking for ctDNA detection and microscopic residual disease assessment in epithelial ovarian cancer Open
View article: 80P Characterization of exceptional survivors from advanced stage high-grade ovarian cancer in the pre-PARP era: A clinical, molecular and immunophenotypic analysis from the VIVROVAIRE & CHIVA GINECO trials
80P Characterization of exceptional survivors from advanced stage high-grade ovarian cancer in the pre-PARP era: A clinical, molecular and immunophenotypic analysis from the VIVROVAIRE & CHIVA GINECO trials Open
View article: Improved Tumor-Type informed compared to Tumor-Informed Mutation Tracking for ctDNA Detection and Microscopic Residual Disease Assessment in Epithelial Ovarian Cancer
Improved Tumor-Type informed compared to Tumor-Informed Mutation Tracking for ctDNA Detection and Microscopic Residual Disease Assessment in Epithelial Ovarian Cancer Open
Background Epithelial ovarian cancer (EOC) is a leading cause of cancer mortality in women, often diagnosed at advanced stages. While first-line treatments improve survival, relapses remain common, with 5-year survival rates below 40%. Cir…
View article: Platinum free interval and clinical benefit of the second-line chemotherapy in recurrent uterine and ovarian carcinosarcoma: a retrospective cohort analysis
Platinum free interval and clinical benefit of the second-line chemotherapy in recurrent uterine and ovarian carcinosarcoma: a retrospective cohort analysis Open
Our results highlight that a subgroup of carcinosarcomas patients exhibits a durable benefit from chemotherapy in the relapse settings, and suggest the use of PFS1, as a proxy of platinum-sensitivity, to select patients who might derive hi…
View article: 41MO ESR1 mutation in untreated endometrial cancer: Prevalence, characteristics and prognostic implications from the UTOLA trial
41MO ESR1 mutation in untreated endometrial cancer: Prevalence, characteristics and prognostic implications from the UTOLA trial Open
View article: 47MO The risk index of early relapse defined by MiROvaR, a miRNA-based classifier, is a potential predictive marker for bevacizumab benefit: A MITO-MANGO-ENGOT study
47MO The risk index of early relapse defined by MiROvaR, a miRNA-based classifier, is a potential predictive marker for bevacizumab benefit: A MITO-MANGO-ENGOT study Open
The introduction of PARP inhibitors (PARPi) has greatly changed Ovarian Cancer (OC) patients' journey. Nonetheless, subgroups of patients still benefit of Bevacizumab (Bev) particularly those at clinical high risk or proficient for BRCA an…
View article: 19P Long-term fatigue after treatments for non-epithelial ovarian cancer survivors
19P Long-term fatigue after treatments for non-epithelial ovarian cancer survivors Open
Non-epithelial rare germ cell tumors (GCT) and sex cord stromal tumors (SCST) are mainly associated with long survival. The treatment includes surgery, frequently combined with chemotherapy (CT). The French Rare Malignant Gynecological Tum…
View article: Supplementary Table S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Supplementary Table S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer Open
prospective collection used to train GIScar (n = 250)
View article: Supplementary Appendix S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Supplementary Appendix S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer Open
PAOLA-1 Investigators
View article: Supplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Supplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer Open
MGMC and GIScar scores among concordant and discordant HRD classification on the clinical collection (n = 469)
View article: Supplementary Figure S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Supplementary Figure S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer Open
PFS in patients according to GIScar (left panel) and MGMC scores (right panel).
View article: Supplementary Table S5 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Supplementary Table S5 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer Open
List of BRCA variants detected by both GIScar tests and MGMC tests
View article: Supplementary Figure S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Supplementary Figure S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer Open
PFS in patients according to GIScar (left panel) and MGMC scores (right panel).
View article: Supplementary Figure S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Supplementary Figure S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer Open
Kaplan–Meier estimates of PFS stratified on Giscar HRD status among inconclusive status of MGMC (n = 43).
View article: Data from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Data from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer Open
Purpose:The optimal application of maintenance PARP inhibitor therapy for ovarian cancer requires accessible, robust, and rapid testing of homologous recombination deficiency (HRD). However, in many countries, access to HRD testing is prob…